Company: FENC
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001558370-25-005563
Chunk: 63

Company: FENNEC PHARMACEUTICALS INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 63
---
 is more than 30 days from the previous year, then notice must be delivered to the Secretary by the later of 60 days prior to the date of the annual meeting or the 10th day following the day on which public announcement of the date of the annual meeting is first made by the Corporation. The notice must comply with the requirements of the SEC’s Rule 14a-19, which requires proponents to provide a timely notice to the Secretary (as described above), setting forth all of the information and disclosures required by Rule 14a-19.

<div align='center'>**ADDITIONAL INFORMATION**</div>

Financial information for the financial year ended December 31, 2024 is provided in the Corporation’s consolidated financial statements and management’s discussion and analysis (“MD&A”), which are included in the Annual Report. Security holders who wish to be added to the mailing list for the annual and interim financial statements and MD&A should complete the appropriate sections of the proxy or contact the undersigned at PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, North Carolina 27709.

The Corporation’s Annual Report on Form 10-K for the fiscal period ended December 31, 2024 (including the consolidated financial statements and MD&A) and other information relating to the Corporation is available on SEDAR at www.sedar.com and at www.sec.gov.

<div align='center'>Page40</div>

#### APPROVAL OF THE BOARD OF DIRECTORSThe contents of this Circular and its sending to Shareholders have been approved by the Board of Directors.DATEDat Research Triangle Park, North Carolina this 25thday of April, 2025.​​​BY ORDER OF THE BOARD OF DIRECTORS​​​​​/s/ Jeff Hackman​Jeff Hackman​Chief Executive Officer​​​​
Page41

SCHEDULE “A-1” FENNEC PHARMACEUTICALS INC. Mandate of the Board of Directors A.Responsibilities The Board of Directors (the “ Board”) of Fennec Pharmaceuticals Inc. (the “ Company”) is responsible for the stewardship of the Company. All directors shall act honestly and in good faith with a view to the best interests of the Company and exercise the care, diligence and skill that a reasonably prudent person would exercise in comparable circumstances. The Board retains plenary authority and power to do all lawful acts and things as are not by law or otherwise directed or required to be exercised or done by the shareholders of the Company or in some other